A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
Clinical data | |
---|---|
Other names | 4-Fluoro-17β-hydroxy-17α-estra-1,3,5(10)-triene-3-carbonitrile |
Drug class | Steroidal antiandrogen |
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C25H27FN2O2 |
Molar mass | 406.501 g·mol−1 |
3D model (JSmol) | |
| |
|
EM-5854 is a steroidal antiandrogen which was under development by Endoceutics, Inc. (formerly Endorecherche, Inc.) for the treatment of prostate cancer.[1][2][3][4][5] It was first described in a patent in 2008, and was further characterized in 2012.[2][4] EM-5854 reached phase I/II clinical trials for the treatment of prostate cancer but development was discontinued in March 2019.[1]
The drug acts as a potent and selective competitive antagonist of the androgen receptor (AR).[4][5] Unlike other steroidal antiandrogens like cyproterone acetate, but similarly to nonsteroidal antiandrogens like bicalutamide and enzalutamide, EM-5854 is a pure or silent antagonist of the AR and shows no intrinsic partial androgenic activity.[4] EM-5854 and its metabolite EM-5855 show 3.7-fold and 94-fold higher affinity for the human AR than bicalutamide (0.66% and 17% of the RBA of metribolone, respectively, compared to 0.18% for bicalutamide).[4][5] They also show dramatically increased antiandrogenic potency relative to bicalutamide in in vivo assays.[4][5][6] On the basis of the available research, it has been said that EM-5854 may possibly have 70- to 140-fold the antiandrogenic potency of bicalutamide in humans.[4] EM-5854 and EM-5855 show little to no affinity for other steroid hormone receptors including the estrogen, progesterone, and glucocorticoid receptors.[4] EM-5854 bears a cyano phenyl group, the structural motif of the nonsteroidal antiandrogens.[7]
Activity | Specifics | Bica | Flu | OH‑Flu | Enza | EM‑5854 | EM‑5855 |
---|---|---|---|---|---|---|---|
AR RBA (%) | Human | 0.18 | NA | 0.17 | 0.07 | 0.66 | 17 |
Metri = 100% | Rat | 0.13 | NA | 0.07 | 0.02 | 0.35 | 2.6 |
Shionogi cells AA activity | Ki (nM) | 81 | NA | NA | 170 | 2.0 | 0.77 |
LNCaP cells (PSA ) AA activity and stim of basal prolif | De50 (nM) (Inhib at 10−7 M (%)) | 1750 (6 ± 10) |
NA | NA | 1380 (−20 ± 3) |
127 (36 ± 7) |
66 (66 ± 1) |
Stim at 10−7 M (%) | 0 ± 1 | NA | NA | 1 ± 1 | 19 ± 1 | 29 ± 2 | |
ER RBA (%) | Rat (E2 = 100%) | 0 | NA | 0 | 0 | 0 | 0 |
PR RBA (%) | Rat (Prom = 100%) | ND | NA | 0 | ND | 0.2 | ND |
GR RBA (%) | Rat (Dexa = 100%) | 0 | NA | 0 | <0.1 | 0 | 0 |
References
- ^ a b "EM 5854 - AdisInsight".
- ^ a b Endorecherche, Inc. Preparation of 17α-substituted steroids as systemic antiandrogens and selective androgen receptor modulators. WO2008124922; 2008 https://patents.google.com/patent/US9284345B2/en
- ^ Zhang X, Lanter JC, Sui Z (September 2009). "Recent advances in the development of selective androgen receptor modulators". Expert Opin Ther Pat. 19 (9): 1239–58. doi:10.1517/13543770902994397. PMID 19505196. S2CID 46186955.
- ^ a b c d e f g h i Gauthier S, Martel C, Labrie F (October 2012). "Steroid derivatives as pure antagonists of the androgen receptor". J. Steroid Biochem. Mol. Biol. 132 (1–2): 93–104. doi:10.1016/j.jsbmb.2012.02.006. PMID 22449547. S2CID 28982450.
- ^ a b c d Cabeza M, Sánchez-Márquez A, Garrido M, Silva A, Bratoeff E (2016). "Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases". Curr. Med. Chem. 23 (8): 792–815. doi:10.2174/0929867323666160210125642. PMC 5412001. PMID 26861003.
- ^ Salvador JA, Carvalho JF, Neves MA, Silvestre SM, Leitão AJ, Silva MM, Sá e Melo ML (February 2013). "Anticancer steroids: linking natural and semi-synthetic compounds". Nat Prod Rep. 30 (2): 324–74. doi:10.1039/c2np20082a. PMID 23151898.
- ^ Fujii S, Kagechika H (June 2019). "Androgen receptor modulators: a review of recent patents and reports (2012-2018)". Expert Opin Ther Pat. 29 (6): 439–453. doi:10.1080/13543776.2019.1618831. PMID 31092069. S2CID 155103197.
External links
- EM-5854 - AdisInsight
- Research programme: androgen receptor antagonists (EM-4350, EM-5855, EM-6537) - AdisInsight
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.
Antropológia
Aplikované vedy
Bibliometria
Dejiny vedy
Encyklopédie
Filozofia vedy
Forenzné vedy
Humanitné vedy
Knižničná veda
Kryogenika
Kryptológia
Kulturológia
Literárna veda
Medzidisciplinárne oblasti
Metódy kvantitatívnej analýzy
Metavedy
Metodika
Text je dostupný za podmienok Creative
Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších
podmienok.
Podrobnejšie informácie nájdete na stránke Podmienky
použitia.
www.astronomia.sk | www.biologia.sk | www.botanika.sk | www.dejiny.sk | www.economy.sk | www.elektrotechnika.sk | www.estetika.sk | www.farmakologia.sk | www.filozofia.sk | Fyzika | www.futurologia.sk | www.genetika.sk | www.chemia.sk | www.lingvistika.sk | www.politologia.sk | www.psychologia.sk | www.sexuologia.sk | www.sociologia.sk | www.veda.sk I www.zoologia.sk